MWVC
ESPR

Morgens Waterfall Vintiadis & Co’s Esperion Therapeutics ESPR Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-35,000
Closed -$1.8M – 33
2020
Q2 		$1.8M Buy
+35,000
New +$1.46M 1.15% 28
2020
Q1 		– Sell
-20,000
Closed -$1.19M – 40
2019
Q4 		$1.19M Buy
+20,000
New +$899K 0.81% 34

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's ESPR Position: Q3 2020 in Review

Morgens Waterfall Vintiadis & Co sold out of Esperion Therapeutics (ESPR) in Q3 2020, closing a stake of 35,000 shares — an estimated $1.8M sold.

Morgens Waterfall Vintiadis & Co first reported a position in ESPR in Q4 2019 and held it in 2 quarters. The position peaked at $1.8M in Q2 2020. 166 funds tracked by Wall St. Rank hold ESPR as of Q3 2020.

  • Morgens Waterfall Vintiadis & Co reported no remaining Esperion Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Morgens Waterfall Vintiadis & Co sold 35,000 Esperion Therapeutics shares in Q3 2020, an estimated $1.8M.
  • Morgens Waterfall Vintiadis & Co first reported a position in Esperion Therapeutics in Q4 2019 and held it in 2 quarters.
  • Morgens Waterfall Vintiadis & Co's Esperion Therapeutics position peaked at $1.8M in Q2 2020.
  • 166 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2020.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q3 2020, filed 16 Nov 2020.